Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin

Liver International

Volumn 28, Issue 10, 2008, Pages 1370-1380

  Vander Borght, Sara ^a,b   Komuta, Mina ^a   Libbrecht, Louis ^a   Katoonizadeh, Aezam ^a   Aerts, Raymond ^a   Dymarkowski, Steven ^a   Verslype, Chris ^a   Nevens, Frederik ^a   Roskams, Tania ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE   (Belgium)

Author keywords

ATP binding cassette transporters; Hepatic progenitor cell; Hepatocellular carcinoma; Keratin 19; Multidrug resistance; Multidrug resistance associated protein 1

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOKERATIN 19; CYTOKERATIN 7; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; STEM CELLS;

EID: 54049149978     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01889.x     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001; 94: 153-6.
2. Adler M, De Pauw F, Vereerstraeten P, et al. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 2008; 14: 526-33.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
4. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-40.
5. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: Review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603.
6. Han B, Zhang JT. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 2004; 4: 31-42.
7. Lage H. ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22: 188-99.
8. Bradley G, Sharma R, Rajalakshmi S, Ling V. P-glycoprotein expression during tumor progression in the rat-liver. Cancer Res 1992; 52: 5154-61.
9. Kato A, Miyazaki M, Ambiru S, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001; 78: 110-5.
10. Ng IOL, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma - a determinant of chemotherapy response. Am J Clin Pathol 2000; 113: 355-63.
11. Lai ECS, Choi TK, Cheng CH, et al. Doxorubicin for unresectable hepatocellular-carcinoma - a prospective-study on the addition of verapamil. Cancer 1990; 66: 1685-7.
12. Richart J, Brunt EM, Di Bisceglie AM. Expression of P-glycoprotein and C-MOAT in human hepatocellular carcinoma - detection by immunostaining. Dig Dis Sci 2002; 47: 2454-8.
13. Takanishi K, Miyazaki M, Ohtsuka M, Nakajima N. Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma. Oncology 1997; 54: 231-7.
14. Vander Borght S, Libbrecht L, Blokzijl H, et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 2005; 207: 471-82.
15. Zollner G, Wagner M, Fickert P, et al. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 2005; 25: 367-79.
16. Ros JE, Libbrecht L, Geuken M, et al. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and hepatocytes in severe human liver disease. J Pathol 2003; 200: 553-60.
17. Ros JE, Roskams TAD, Geuken M, et al. ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut 2003; 52: 1060-7.
18. Vander Borght S, Libbrecht L, Katoonizadeh A, et al. Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/ reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: Possible functional consequences. J Histochem Cytochem 2006; 54: 1051-9.
19. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.
20. Robrechts C, De Vos R, Van den Heuvel M, et al. Primary liver tumour of intermediate (hepatocyte bile duct cell) phenotyp: A progenitor cell tumour? Liver 1998; 18: 288-93.
21. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006; 25: 3818-22.
22. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004; 40: 667-76.
23. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-51.
24. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003; 94: 851-7.
25. Vaneyken P, Sciot R, Paterson A, et al. Cytokeratin expression in hepatocellular-carcinoma - an immunohistochemical study. Human Pathol 1988; 19: 562-8.
26. Wu PC, Fang JWS, Lau VKT, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers - clinical and biological implications. Am J Pathol 1996; 149: 1167-75.
27. Aishima S, Nishihara Y, Kuroda Y, et al. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation - subdivision and comparison with ordinary hepatocellular carcinoma. Am J Surg Pathol 2007; 31: 783-91.
28. Roelofsen H, Vos TA, Schippers IJ, et al. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997; 112: 511-21.
29. Edmondson HA, Steiner PE. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
30. Hsia CC, Evarts RP, Nakatsukasa H, et al. Occurrence of oval-type cells in hepatitis-B virus-associated human hepatocarcinogenesis. Hepatology 1992; 16: 1327-33.
31. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004; 40: 298-304.
32. Nies AT, Konig J, Pfannschmidt M, et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 2001; 94: 492-9.
33. Leslie EM, Deeley RG, Cole SPC. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001; 167: 3-23.
34. Laupeze B, Amiot L, Payen L, et al. Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci 2001; 68: 1323-31.
35. + cells. Eur J Haematol 2003; 71: 119-23.
36. Franco R, Panayiotidis MI, Cidlowski JA. Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation. J Biol Chem 2007; 282: 30452-65.
37. Hammond CL, Marchan R, Krance SM, Ballatori N. Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J Biol Chem 2007; 282: 14337-47.
38. Berger W, Setinek U, Hollaus P, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol 2005; 131: 355-63.
39. Filipits M, Pohl G, Rudas M, et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian breast and colorectal cancer study group. J Clin Oncol 2005; 23: 1161-8.